key: cord-0320136-9iv58r5i
authors: Pardieck, Iris N.; van der Gracht, Esmé T.I.; Veerkamp, Dominique M.B.; Behr, Felix M.; van Duikeren, Suzanne; Beyrend, Guillaume; Rip, Jasper; Nadafi, Reza; van der Sluis, Tetje C.; Nejad, Elham Beyranvand; Mülling, Nils; Brasem, Dena J.; Camps, Marcel G.M.; Myeni, Sebenzile K.; Bredenbeek, Peter J.; Kikkert, Marjolein; Kim, Yeonsu; Cicin-Sain, Luka; Abdelaal, Tamim; van Gisbergen, Klaas P.J.M.; Franken, Kees L.M.C.; Drijfhout, Jan Wouter; Melief, Cornelius J.M.; Zondag, Gerben C.M.; Ossendorp, Ferry; Arens, Ramon
title: A third vaccination with a single T cell epitope protects against SARS-CoV-2 infection in the absence of neutralizing antibodies
date: 2021-12-18
journal: bioRxiv
DOI: 10.1101/2021.12.15.472838
sha: 2f5919082c485d4acd889b346f4c8212c1393430
doc_id: 320136
cord_uid: 9iv58r5i

Understanding the mechanisms and impact of booster vaccinations can facilitate decisions on vaccination programmes. This study shows that three doses of the same synthetic peptide vaccine eliciting an exclusive CD8+ T cell response against one SARS-CoV-2 Spike epitope protected all mice against lethal SARS-CoV-2 infection in the K18-hACE2 transgenic mouse model in the absence of neutralizing antibodies, while only a second vaccination with this T cell vaccine was insufficient to provide protection. The third vaccine dose of the single T cell epitope peptide resulted in superior generation of effector-memory T cells in the circulation and tissue-resident memory T (TRM) cells, and these tertiary vaccine-specific CD8+ T cells were characterized by enhanced polyfunctional cytokine production. Moreover, fate mapping showed that a substantial fraction of the tertiary effector-memory CD8+ T cells developed from remigrated TRM cells. Thus, repeated booster vaccinations quantitatively and qualitatively improve the CD8+ T cell response leading to protection against otherwise lethal SARS-CoV-2 infection. Summary A third dose with a single T cell epitope-vaccine promotes a strong increase in tissue-resident memory CD8+ T cells and fully protects against SARS-CoV-2 infection, while single B cell epitope-eliciting vaccines are unable to provide protection.

The coronavirus disease 2019 pandemic, caused by the β-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global health emergency. Vaccines eliciting neutralizing antibodies against the Spike protein of SARS-CoV-2 have shown high effectiveness (1, 2) . However, the level of neutralizing antibodies declines after vaccination (3) and at-risk patient groups, including transplant recipients, individuals suffering from B cell leukemia, and auto-immune disease patients on selected immunosuppressive regimens (such as B cell depleting reagents), exhibit lower humoral and cellular immunity after vaccination (4) (5) (6) . Moreover, the mutation rate of coronaviruses is substantial and certain mutations in the Spike protein of SARS-CoV-2 have emerged that can lead to a decline in neutralizing antibody-mediated protection (7, 8) . In order to address this clinical problem, a third vaccination for solid organ transplant recipients is becoming the standard of care in more and more countries, and supplementary T cell-focused strategies have been suggested (9, 10) .

While boosters with the current vaccines likely lead to the generation of enhanced levels of neutralizing antibodies, it is uncertain if this will improve protection in the aforementioned risk groups and provide protection against the emergence of novel SARS-related viruses. However, a third vaccination may also lead to enhanced T cell responses, which is expected to contribute to the control of SARS-CoV-2 infection as evidenced by their association to disease severity and protection in humans (11) (12) (13) (14) (15) (16) and animal models (17, 18) . Moreover, T cell-focused vaccines can be directed to more conserved regions of the coronavirus, which may lead to a broad T cell-based cross-protection against multiple coronavirus strains and likely independently expands the protection provided by antibodies. Such T cell-mediated protection is important given the potential emergence of similar viruses in the future that pose a significant threat to global public health. Previous studies showed that T cells can mediate protection by themselves against SARS-CoV-1 (19, 20) but whether T cell-eliciting vaccines can protect against SARS-CoV-2 is unclear. Here, we demonstrate that a peptide vaccine exclusively eliciting CD8 + T cell responses against a single epitope present in the Spike protein delivers full protection against SARS-CoV-2, provided that the vaccine was administered in a double booster regimen, leading to the induction of high numbers of circulating and tissue-resident memory T (T RM ) cells. A third vaccination was especially critical to achieve cytokine polyfunctionality and induction of elevated T RM cell numbers in the lungs and liver, and additionally fueled retrograde migration of T RM cells into the circulation. Thus, booster vaccinations eliciting strong CD8 + T cell responses are a promising strategy against coronavirus-mediated disease independent of neutralizing antibodies.

Single B and T cell epitope vaccines can provide effective approaches against a variety of pathogens and malignancies (21) (22) (23) (24) . To investigate the efficacy of linear B cell epitope vaccines against SARS-CoV-2 infection, we selected five different linear epitopes present in the Spike protein that were considered to potentially elicit protective antibodies (25) (26) (27) . To test their immunogenicity, C57BL/6 mice were vaccinated with synthetic long peptide (SLP)-based vaccines each containing a single B cell epitope. After three vaccinations, however, these SLP vaccines did not elicit Spike-specific antibody responses (Supplementary Fig 1A) . To improve this synthetic vaccine, we hypothesized that lack of CD4 + T cell help may underlie the ineffective antibody responses. In line with that, addition of SLPs containing the universal helper T-cell epitope PADRE or coupling of the PADRE epitope to the linear B cell epitopes, improved the Spike-specific IgG antibody response (Fig 1A, Supplementary Fig 1B) . Next, we tested the particular influence of the adjuvants CpG and Incomplete Freund's Adjuvant (IFA) on the specific antibody induction of the B cell-SLP vaccines. The combination of these adjuvants acted synergistically to elicit high levels of antibodies against a single epitope present in the Spike protein, which correlated with a higher induction of PADRE-specific CD4 + T cell responses (Fig 1B-D) . Depletion of CD4 + T cells during the vaccination period resulted in a decreased spike-specific antibody response (Supplementary Fig 1C) , highlighting the need for CD4 + T cells for an optimal IgG response. CD8 + T cell responses were not induced by the B cell-SLP vaccines (Supplementary Fig 1D) .

To determine whether immunization with optimized linear B cell epitope vaccines enables protective immune responses against SARS-CoV-2, we used transgenic mice expressing the human angiotensin Iconverting enzyme 2 (ACE2) receptor under the regulation of the cytokeratin 18 (K18) promoter, which develop severe lung disease in response to SARS-CoV-2 infection (28) . The K18-hACE2 mice were vaccinated three times in a two week interval with either one CpG/IFA adjuvanted PADRE-coupled B cell-SLP vaccine or a combination of the five different B cell-SLP vaccines (Fig 1E) . Spike-specific IgG antibody responses were elicited and reached high titers after the third (3 rd ) vaccination (Fig 1F) . Four weeks after the 3 rd vaccination, the K18-hACE2 mice were challenged intranasally with a lethal dose of SARS-CoV-2 and body weight was measured daily as a parameter of disease. Both unvaccinated mice and mice that were vaccinated three times with the B cell-SLPs succumbed to SARS-CoV-2 infection (Fig 1G, 1H) , showing that SLP vaccination with these linear B cell epitopes was not able to protect against SARS-CoV-2 infection.

This inability of protection correlated with the deficiency of antibodies against the single epitopes to neutralize virus cell entry (Fig 1I) . In contrast, a DNA vaccine encoding the entire Spike protein fully protected K18-hACE2 transgenic mice and this correlated with the ability to elicit neutralizing Spikespecific antibodies (Supplementary Fig 1E-1H ). In addition, this DNA vaccine also induced a Spike-specific CD4 + and CD8 + T cell response (Supplementary Fig 1I) . Overall, these results indicate that antibody responses to these single linear B cell epitopes are inferior for induction of neutralizing antibodies, although, we cannot exclude the possibility that single linear B cell epitopes exist that can elicit neutralizing antibodies. Nevertheless, antibody responses induced by vaccine platforms encoding properly folded proteins presenting conformational B cell epitopes are able to generate neutralizing antibodies and provide protection against SARS-CoV-2 infection.

To determine whether an immune response induced by a single CD8 + T cell epitope vaccine was able to protect against SARS-CoV-2 infection, K18-hACE2 transgenic mice were vaccinated once, twice or three times with an SLP encoding an immunodominant CD8 + T cell epitope present in the Spike protein of SARS-CoV-1 and SARS-CoV-2 (29) . Five weeks after the final vaccination, mice were intranasally challenged with a lethal dose of SARS-CoV-2 (Fig 2A) . SLP vaccination induced a Spike 539-546 -specific CD8 + T cell response in all mice, which increased with each booster immunization and remained elevated after contraction (Fig   2B-D) . CD4 + T cell responses and spike-specific antibodies were not induced (Supplementary Fig 1J, 1K) .

Whereas 75% of the non-vaccinated mice succumbed to SARS-CoV-2 challenge, 66% and 50% of the mice that received one or two vaccinations, respectively, succumbed. Strikingly, all mice that received a 3 rd vaccine dose recovered from the SARS-CoV-2 challenge despite initial weight loss (Fig 2E, 2F) . Thus, a third vaccination with an SLP containing a single CD8 + T cell epitope protects against lethal SARS-CoV-2 infection.

Next, we aimed to determine the impact and underlying mechanisms of sequential vaccinations on the memory differentiation of the elicited antigen-specific CD8 + T cells. Three times vaccinated mice had higher frequencies of Spike 539-546 -specific CD8 + T cells in the spleen compared to two times vaccinated mice, which in turn had higher frequencies compared to once vaccinated mice (Fig 3A) . Remarkably, in the liver and lungs, the 3 rd vaccination resulted also in a notably higher Spike 539-546 -specific CD8 + T cell response compared to the single or double vaccination. In the liver, this difference was mainly due to an increment of the CD69 + T RM cells and in the lungs due to enhancement of both the circulating and T RM cells (Fig 3A, Supplementary Fig 2A) . To investigate the effector potential of these Spike 539-546 -specific CD8 + T cells, the polyfunctional cytokine production capacity of the vaccine-specific CD8 + T cells was determined.

The 2 nd vaccination markedly increased the magnitude of the polycytokine producing CD8 + T cells (IFNγ + /TNF + , IFN-γ + /TNF + /IL-2 + ) in spleen, liver and lungs, which was further increased substantially by the 3 rd vaccination. (Fig 3B) .

To validate these findings for other viral epitopes, we vaccinated mice with SLP vaccines containing the model antigen GP [34] [35] [36] [37] [38] [39] [40] [41] derived from lymphocytic choriomeningitis virus (LCMV) (Fig 3C) . As observed with the Spike 539-546 -SLP immunization, each subsequent vaccination with GP 34-41 -SLP, increased the magnitude of the vaccine-specific CD8 + T cell response, and this response remained higher after contraction (Fig 3D-F) . Moreover, the circulating GP 34-41 -specific CD8 + T cells in the spleen where significantly increased upon each vaccination, while in the liver and lungs, the 3 rd vaccination resulted in a much higher magnitude of the GP 34-41 -specific CD8 + T RM cells (Fig 3G, Supplementary Fig 2B) . In addition, these increments were also reflected in increased polyfunctional cytokine producing GP 34-41 -specific CD8 + T cells in the spleen, liver and lungs (Fig 3H) . Thus, sequential booster vaccinations result in programming significant and durable expansion of polyfunctional vaccine-specific CD8 + T cells.

Boosting impact on the phenotype of vaccine-specific CD8 + T cells.

Next, we aimed to examine the phenotype of the vaccine-boosted CD8 + T cells. We first performed analysis of these cells in the blood circulation using the canonical markers CD62L, CD44 and KLRG1, which define their state of differentiation. Both conventional flow cytometric analysis and analysis using Cytosplore, which incorporates approximated t-distributed stochastic neighbor embedding (A-tSNE) algorithms for subset definition (30) , highlighted that the memory phenotype of the GP 34-41 -specific CD8 + T cells in blood is clearly skewed towards an effector-memory like state (CD44 high CD62L -KLRG1 + ) by one booster vaccination, and that the 2 nd booster vaccination skewed this phenotype slightly further (Fig 4A,   4B ).

To gain further insight into the phenotype of the vaccine-specific CD8 + T cells upon sequential vaccination, we studied these cells in the tissues using single-cell high dimensional mass cytometry with a 39-antibody panel targeting markers of cellular activation and differentiation (31) (Supplementary Fig 2C, Supplementary Table 1 ). Visualization of the distribution of GP 34-41 -specific CD8 + T cells in one tSNE analysis based on density and marker expression indicated a differential distribution of these cells upon booster vaccination in the spleen, liver and lungs. While the 1 st vaccination was phenotypically disparate from the 2 nd vaccination and 3 rd vaccination, the 2 nd and 3 rd vaccination were overlapping but still showed some distinction (Fig 4C) . To capture this pattern, principal component analysis (PCA) was performed based on the cluster frequencies of the GP 34-41 -specific memory CD8 + T cells in the spleen, liver and lungs and this confirmed the clear distinction between clusters present in one-time vaccinated versus clusters in two or three times vaccinated mice (Fig. 4D ). Subsequently, we performed a dual tSNE analysis on all samples of GP 34-41 -specific CD8 + T cells and visualized the segregation based on vaccination-associated patterns in more depth (Fig. 4E) . Visualization of the tSNE map values of the GP 34-41 -specific CD8 + T cell clusters corroborated that the 2 nd and 3 rd vaccination-specific phenotypes had considerable overlaps. To establish the (dis)similarity of the CD8 + T cell clusters in multiple vaccinations a Jensen-Shannon (JS) divergence analysis was performed (Fig 4F) . A low JS distance was found when comparing antigen-specific CD8 + T cells induced upon 2 nd and 3 rd vaccinations, indicating a high similarity between cells induced by these vaccinations, whereas a higher JS distance was found when comparing 1 st to 2 nd vaccinations or 1 st to 3 rd vaccinations.

Visualization of the particular marker expression of the total GP 34-41 -specific CD8 + T cell population in the tissues indicated that the activation-associated NK cell receptors KLRG1 and NKG2A, the Ly6 family GPIanchored surface molecules Sca-1 and Ly6C, the chemokine receptor CX3CR1 and the ectonucleotidase CD39 connected more to the 2 nd and 3 rd vaccination while CD62L expression related to single-dose vaccination (Fig 4G, 4H) . To gain further insight into the antigen-specific CD8 + T cell phenotypes in the different organs, we analyzed the phenotype of these cells per tissue using FlowSOM (32) and Cytofast (33, 34) , and categorized the large clusters into the three main memory T cell subsets (i.e. T CM , T EM , and T RM ) based on their CD69 and CD62L expression. In the spleen and lungs, the percentage CD69 -CD62L -T EMlike cells expressing KLRG1, NKG2A, Sca-1, Ly6C, CX3CR1 within the GP 34-41 -specific CD8 + T cell population, increased primarily upon the first booster vaccination, while the CD69 -CD62L + T CM subsets decreased ( Fig   4I) . The phenotype of CD69 + GP 34-41 -specific CD8 + T RM cells in the liver was slightly affected upon the 2 nd boosting, and resulted in reduction of CD11c + CD122 + PD-1 -T RM cells and an increase in CD11c + CD122 -PD-1 + T RM cells (Fig 4I) .

To validate the strong induction of the T EM -like phenotype by booster vaccination, we determined the percentage of cells expressing the T EM markers, which provided the most distinction (i.e. KLRG1, CX3CR1, Ly6C), by flow cytometry. Indeed, vaccine-specific CD8 + T cells in the spleen co-expressing Ly6C + KLRG1 + and CX3CR1 + KLRG1 + increased most profoundly upon the first booster and this further increased upon the second booster while the CD62L + KLRG1cells followed an opposite pattern ( Fig 4J) . Moreover, this effect was also apparent upon vaccination with the Spike 539-546 -SLPs (Supplementary Fig 2D) . Finally, the metabolic effector-memory cell properties were analyzed. Uptake of the glucose analog 2-(N-(7nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) and expression of the glucose transport (GLUT-1) (Fig 4K) reduced following each vaccination, indicating lower glycolysis, which may relate to a different metabolic efficiency and to a non-exhausted state (35) . Thus, the second vaccination had a profound system-wide impact on the phenotype of the vaccine-induced CD8 + T cells, which resulted in the increment of effector-memory-like cells characterized by activation markers and chemokine receptors.

To fate map the T RM cell progeny upon booster vaccination, we used a reporter system based on the T RMrestricted transcription factor Hobit to evaluate the development of the T RM cells (36) . Here, Hobit lineage tracer (LT) mice, which were generated by crossing CD45.1 Hobit reporter OT-I mice with ROSA26-eYFP mice, were used. CD8 + T cells in these mice recognize the epitope SIINFEKL (OVA 257-264 ) and report active Hobit expression (by tdTomato expression) and previous Hobit expression (by YFP expression), which allows the detection of ex-Hobit + cells (ex-T RM ; tdTomato -YFP + ). First, we tested vaccination with OVA 257-264 -SLP in a prime-boost-boost setting, and this resulted in vaccine-specific CD8 + T cell responses that are comparable to other SLPs (Fig 5A) . Next, we adoptively transferred the OT-I CD8 + T cells of the Hobit reporter × ROSA26-eYFP LT mice into naïve wild-type mice that received subsequent OVA 257-264 -SLP vaccinations in a prime-boost-boost setting. As expected, an increase of CD8 + T RM cells (CD69 + tdTomato + YFP + ) was observed in the liver after the 2 nd and 3 th vaccination, which were all co-expressing CD38 (Fig   5B, 5C) . Remarkably, in particular the 3 rd vaccination induced the emergence of ex-T RM cells in the liver, spleen and blood circulation, and the formation of these cells was characterized by a T EM phenotype (CD44 + CD62L -KLRG1 + ) (Fig 5C-F) . Thus, ex-T RM cells with a T EM phenotype are induced upon sequential SLP vaccination and are present in the blood circulation, spleen and liver.

Here, we have investigated the capacity of single B cell and T cell epitope-containing peptide vaccines to elicit protection against SARS-CoV-2 infection in the K18-hACE2 transgenic mouse model, and found that only a third vaccination with a long peptide harboring a single T cell epitope provided full protection. To our knowledge this is the first study to show that vaccine-elicited CD8 + T-cells without the aid of virusspecific CD4 + helper T cells or neutralizing antibodies can protect against SARS-CoV-2, albeit provided in a booster setting requiring at least 2 boosters. These results may be of interest for the current discussion regarding a third vaccination, as the current vaccines elicit virus-specific T cells (4) . In addition, these results may also guide the development of T-cell focused vaccines, which could be of utmost importance for susceptible patient groups such as transplantation and leukemia patients, and patients with autoimmune diseases treated with anti-CD20 antibodies such as rituximab. These patients have impaired antibody responses, and therefore may depend on robust T cell-eliciting vaccines for protection.

The DNA vaccine platform we used encoding Spike protein was highly efficient in generating neutralizing antibodies and resulted in protection against SARS-CoV-2 infection. Although, our results indicated that antibody responses to single linear B cell epitopes are inferior for induction of neutralizing antibodies, we cannot exclude the possibility that single linear B cell epitopes exist that can elicit neutralizing antibodies.

In addition, in settings in which antibodies mediate protection by other mechanisms, such as antibodydependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC) (37), the B cell-SLP platform may be valuable. In this respect, the addition of CpG and IFA as adjuvants and the insertion of a CD4 + T helper cell epitope to the linear B cell epitope vaccine was indispensable to elicit antibody responses.

In-depth studies using the T cell epitope SLP vaccines indicated that a third vaccination resulted in superior generation of CD8 + T EM cells in the circulation and also of CD8 + T RM cells in liver and lungs. The CD8 + T cells elicited upon a third dose vaccination are functionally and phenotypically modulated as evidenced by activation-associated cell-surface markers and their polyfunctional cytokine production. The latter is in line with a recent study in humans, which indicated that a third vaccination in kidney transplant recipients leads to increased circulating polyfunctional CD4 + T cells (38) . It would be of interest to decipher whether a third dose of the mRNA vaccine in healthy individuals, which is more effective against severe COVID-19related outcomes compared to two doses (39) , also associates to increased T cell immunity.

The increase of T EM and T RM cells in the lungs after the third vaccination as reported here may be critical as the lungs are the primary entry point for SARS-CoV-2. Nevertheless, the circulating vaccine-induced T cells in the spleen and blood may also contribute to protection as well as these cells can rapidly migrate into the infected lung tissue and exert effector function. Moreover, also the efficient formation of the T RM cells in the liver, which was mainly observed after the third vaccination, may contribute to protection as these cells have superior potential to differentiate into ex-T RM cells (40) .

In conclusion, a third vaccination with a synthetic vaccine containing a single CD8 + T cell epitope results in protection against SARS-CoV-2. This protection can be explained by an improved quantitative and qualitative CD8 + T cell response after the third vaccination that is highlighted by higher numbers of virusspecific T EM and T RM cells with polyfunctional cytokine capacity.

Mice. Wild-type C57BL/6 mice were obtained from Charles River Laboratories, Jackson Laboratory or Janvier Labs. The K18-hACE2 transgenic mice, expressing the human ACE2 receptor (hACE2) under control of the cytokeratin 18 (K18) promoter (41) , were obtained from the Jackson Laboratory (B6.Cg-Tg(K18-ACE2)2Prlmn/J), and bred in-house. The Hobit reporter × ROSA26-eYFP LT mice were previously described (36) . Following 1h incubation at 37 °C and 5% CO 2 , the inoculum was removed, and 1.5% methylcellulose overlay was added. Infected cells were incubated for 3 days at 37 °C and 5% CO 2 , prior to crystal violet staining and plaque counting.

Single-cell preparations. Peripheral blood was collected from the tail vein. Splenocytes were obtained by mincing the tissue through cell strainers. Blood cells and splenocytes were depleted of erythrocytes using ammonium chloride lysis buffer. To remove remaining circulating blood cells from the liver and lungs, mice were perfused with 20 ml PBS containing 2 mM EDTA. Next, liver and lungs were cut into small pieces using surgical knives, and the tissue was resuspended in 3.5 ml or 1 ml, respectively, of IMDM containing 250 U/ml collagenase type 1-A (C2674, Sigma) and 20 μg/ml DNase I (D5025, Sigma). After incubation with collagenase/DNase for 25 minutes at 37°C, liver and lung tissue was dissociated into single-cell suspensions using 70 μm cell strainers, and subsequently lymphocytes were isolated using a Percoll (GE Healthcare) gradient. GLUT-1 (clone EPR3915, Abcam). Zombie Aqua (Biolegend) staining was used to exclude dead cells.

Glucose uptake was measured by the uptake of glucose analogue 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4yl)amino)-2-deoxyglucose (2-NBDG, Life Technologies). Cell surface and intracellular cytokine stainings of splenocytes and blood lymphocytes were performed as described (42) . PADRE-specific CD4 + T cells were quantified using an MHC class II tetramer for the epitope (AKFVAAWTLKAA) (NIH Tetramer Core Facility).

Spike 539-546 -specific, GP 34-41 -specific or OVA 257-264 -specific CD8 + T cells were quantified using MHC class I tetramers generated in-house. For examination of intracellular cytokine production, single cell suspensions were stimulated with short peptides for 5h in the presence of brefeldin A or with long peptides for 8h of which the last 6h in presence of brefeldin A (Golgiplug; BD Pharmingen). Flow cytometric acquisition was performed on a BD Fortessa flow cytometer (BD Biosciences) or Aurora Cytek spectral analyzer, and samples were analyzed using FlowJo software (TreeStar).

Metal-conjugated antibodies were either purchased from Fluidigm or were generated by conjugation of lanthanide metal isotopes to anti-mouse antibodies using the Maxpar X8

Polymer method according to the manufacturer's protocol (Fluidigm). Cisplatins 194 and 198 and Bismuth 209 were conjugated to anti-mouse monoclonal antibodies using protocols previously described (43, 44) .

All in-house conjugated antibodies were diluted to 0.5 mg/ml in antibody stabilizer supplemented with 0.05% sodium azide (Candor Biosciences). Serial dilution staining was performed on mouse lymphocytes to determine appropriate antibody dilution.

The CyTOF staining was performed as described elsewhere (31). In brief, around 3 × 10 6 cytometry data analysis focused on the antigen-specific CD8 + T cells. For the selection, we set our gating strategy to live single cells, positive for CD45, and excluded reference beads. The live CD45 + gated files were compensated using Catalyst (45) . Subsequently, MHC class I tetramer-specific CD8 + T cells were selected in FlowJo for subsequent analysis. Next, marker expression was ArcSinh5 transformed and subjected to dimensionality reduction analyses and cluster identification using Cytosplore (30) or FlowSOM (32) . For Cytosplore analysis, samples were analysed by hierarchical stochastic neighbor embedding (HSNE) (46) based on approximated t-distributed stochastic neighbor embedding (A-tSNE) (47) . The similarity between tSNE maps was quantified using the Jensen-Shannon (JS) divergence as previously described (31). The JS divergence values ranged from 0 (indicating identical distributions) to 1 (indicating disjoint distributions). The dual tSNE analysis was performed to quantify the individual samples similarity based on the clusters composition as previously described (31, 48). FlowSOM was used for the identification of vaccination and tissue-specific clusters. Using FlowSOM, 14 clusters were identified per analysis. Subsequently, Cytofast (33, 34) was used for visualization and quantification of cell clusters. T RM (CD62L -CD69 + ), T CM (CD62L + CD69 -) and T EM (CD62L -CD69 -) CD8 + T cell clusters were selected by expression of CD62L and CD69. Visualization of heatmaps and selection of clusters based on the size of the cluster (abundance of at least >5% of total) and significance was performed as previously described (31).

Adoptive T cell transfers. Spleens of OT-I Hobit reporter × ROSA26-eYFP LT mice were isolated and subsequently CD8 + T cells were isolated by negative selection using MicroBeads (130-104-075, Miltenyi Biotec) according to the manufacturer's protocol. Splenic CD8 + T cells were adoptively transferred via retro-orbital injection into naïve CD45.2 mice.

Statistical analysis. Statistical analyses were performed using Cytofast or GraphPad Prism (La Jolla, CA, Unites States). One-way ANOVA and log-rank (Mantel-Cox) survival test were used for statistical analysis.

All P values were two-sided, and P < 0.05 was considered statistically significant. Spike 539-546 -specific CD8 + T cells in blood at day 62 after vaccination. Bar graphs represent means ± SEM. Symbols represent individual mice. One-way ANOVA was performed to determine statistical significance. Representative data of two independent experiments. One-way ANOVA test with repeated measurements was used for statistical analysis. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

T cell-oriented strategies for controlling the COVID-19 pandemic

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

CD8(+) T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients

CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Mapping and role of T cell response in SARS-CoV-2-infected mice

Correlates of protection against SARS-CoV-2 in rhesus macaques

T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice

Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses

Adenoviral vaccines promote protective tissue-resident memory T cell populations against cancer

PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors

Single-epitope DNA vaccination prevents exhaustion and facilitates a broad antiviral CD8+ T cell response during chronic viral infection

Single B or T-cell epitope-based DNA vaccine using modified vector induces specific immune response against hepadnavirus

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity

SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein

Interactive Immune Cell Phenotyping for Large Single-Cell Datasets

Memory CD8+ T cell heterogeneity is primarily driven by pathogen-specific cues and additionally shaped by the tissue environment. iScience

Using self-organizing maps for visualization and interpretation of cytometry data

Cytofast: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations

Visualization and Quantification of High-Dimensional Cytometry Data using Cytofast and the Upstream Clustering Methods FlowSOM and Cytosplore

Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host

Tissueresident memory CD8(+) T cells shape local and systemic secondary T cell responses

Nonneutralizing Antibodies Directed at Conservative Influenza Antigens

B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Discrete tissue microenvironments instruct diversity in resident memory T cell function and plasticity

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

Differential B7-CD28 costimulatory requirements for stable and inflationary mouse cytomegalovirus-specific memory CD8 T cell populations

Platinum-conjugated antibodies for application in mass cytometry

Systemic Immunity Is Required for Effective Cancer Immunotherapy

Visual analysis of mass cytometry data by hierarchical stochastic neighbour embedding reveals rare cell types

Mass Cytometry of the Human Mucosal Immune System Identifies Tissue-and Disease-Associated Immune Subsets